Redhill Biopharma
RDHL
8 hedge funds and large institutions have $12.9M invested in Redhill Biopharma in 2014 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
33% more funds holding
Funds holding: 6 → 8 (+2)
8% more capital invested
Capital invested by funds: $11.9M → $12.9M (+$945K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$10.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$114K |
RDHL Hedge Fund Activity: Q4 2014 in Review
8 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q4 2014, worth a combined $12.9M — up 7.9% from $11.9M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new RDHL positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $10.4K. The largest seller was Broadfin Capital, cutting an estimated $114K.
- 8 institutional investors held Redhill Biopharma (RDHL) as of Q4 2014, up from 6 in Q3 2014.
- Funds reported $12.9M of Redhill Biopharma stock for Q4 2014, up 7.9% quarter-over-quarter.
- 2 funds opened new Redhill Biopharma positions in Q4 2014 and 0 closed out, a net change of +2 holders.
- The largest Redhill Biopharma buyer in Q4 2014 was Tower Research Capital (TRC), an estimated $10.4K added.
- The largest Redhill Biopharma seller in Q4 2014 was Broadfin Capital, an estimated $114K sold.
Based on aggregated 13F filings for Q4 2014.